
|Videos|January 19, 2023
Efficacy and Safety of JAK inhibitors for AD
Author(s)Brett King, MD, PhD, Alexandra K. Golant, MD
Experts in atopic disease management review the efficacy and safety data of the JAK inhibitor class, highlighting the importance of time to treatment response and itch reduction.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
Expert Panel Unanimously Backs DecisionDx-Melanoma for Guiding Personalized Cancer Care
4
Considering Biologics and Shared Decision-Making in Moderate to Severe Plaque Psoriasis: Part 2
5





















